Literature DB >> 22223339

Identification of small molecule activators of the janus kinase/signal transducer and activator of transcription pathway using a cell-based screen.

Zheng Fu Tai1, Guo Lin Zhang, Fei Wang.   

Abstract

Type I interferons (IFN-α/β) have been widely used in the treatment of many viral and malignant diseases by activation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway, but the side effects of protein-based IFN therapy severely limit their clinical use. Discovering small molecules to activate the JAK/STAT pathway will greatly facilitate the development of new drugs which have similar pharmacological function to IFNs but with fewer side effects. To screen a natural products-based library, we established a cell-based screening assay using human hepatoma HepG2 cells stably transfected with a plasmid where the luciferase reporter activity is driven by interferon α-stimulated response element (ISRE), the motif specifically recognized by type I IFN-induced activation of JAK/STAT pathway. Among 1,431 natural product compounds screened, four compounds (emodin, quercetin, apigenin and luteolin) were identified as activators of the JAK/STAT pathway. Further studies demonstrated that these four compounds could increase the endogenous antiviral gene expression regulated by the IFN-activated JAK/STAT pathway. The identified small molecule activators are valuable for structural modification and warrant further investigation for use in new antiviral drugs as IFN mimics or adjuvants.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22223339     DOI: 10.1248/bpb.35.65

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  8 in total

1.  Modulation of PI3K-LXRα-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin.

Authors:  Sandra Pisonero-Vaquero; María V García-Mediavilla; Francisco Jorquera; Pedro L Majano; Marta Benet; Ramiro Jover; Javier González-Gallego; Sonia Sánchez-Campos
Journal:  Lab Invest       Date:  2014-02-03       Impact factor: 5.662

2.  Emodin potentiates the antiproliferative effect of interferon α/β by activation of JAK/STAT pathway signaling through inhibition of the 26S proteasome.

Authors:  Yujiao He; Junmei Huang; Ping Wang; Xiaofei Shen; Sheng Li; Lijuan Yang; Wanli Liu; Apichart Suksamrarn; Guolin Zhang; Fei Wang
Journal:  Oncotarget       Date:  2016-01-26

3.  Dietary apigenin potentiates the inhibitory effect of interferon-α on cancer cell viability through inhibition of 26S proteasome-mediated interferon receptor degradation.

Authors:  Sheng Li; Li-Juan Yang; Ping Wang; Yu-Jiao He; Jun-Mei Huang; Han-Wei Liu; Xiao-Fei Shen; Fei Wang
Journal:  Food Nutr Res       Date:  2016-06-28       Impact factor: 3.894

4.  High-throughput screening for small molecule inhibitors of the type-I interferon signaling pathway.

Authors:  Elita Yuliantie; Xinchuan Dai; Dehua Yang; Peter J Crack; Ming-Wei Wang
Journal:  Acta Pharm Sin B       Date:  2018-07-10       Impact factor: 11.413

5.  Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity.

Authors:  Marianne Lucas-Hourani; Daniel Dauzonne; Pierre Jorda; Gaëlle Cousin; Alexandru Lupan; Olivier Helynck; Grégory Caignard; Geneviève Janvier; Gwénaëlle André-Leroux; Samira Khiar; Nicolas Escriou; Philippe Desprès; Yves Jacob; Hélène Munier-Lehmann; Frédéric Tangy; Pierre-Olivier Vidalain
Journal:  PLoS Pathog       Date:  2013-10-03       Impact factor: 6.823

6.  Identification of a small molecule that primes the type I interferon response to cytosolic DNA.

Authors:  Samira Khiar; Marianne Lucas-Hourani; Sébastien Nisole; Nikaïa Smith; Olivier Helynck; Maryline Bourgine; Claude Ruffié; Jean-Philippe Herbeuval; Hélène Munier-Lehmann; Frédéric Tangy; Pierre-Olivier Vidalain
Journal:  Sci Rep       Date:  2017-05-31       Impact factor: 4.379

7.  Dietary quercetin potentiates the antiproliferative effect of interferon-α in hepatocellular carcinoma cells through activation of JAK/STAT pathway signaling by inhibition of SHP2 phosphatase.

Authors:  Ighodaro Igbe; Xiao-Fei Shen; Wei Jiao; Zhe Qiang; Teng Deng; Sheng Li; Wan-Li Liu; Han-Wei Liu; Guo-Lin Zhang; Fei Wang
Journal:  Oncotarget       Date:  2017-11-20

8.  A 2-Benzylmalonate Derivative as STAT3 Inhibitor Suppresses Tumor Growth in Hepatocellular Carcinoma by Upregulating β-TrCP E3 Ubiquitin Ligase.

Authors:  Ting Peng; Orawan Wonganan; Zhonghui Zhang; Jialing Yu; Ruiying Xi; Yu Cao; Apichart Suksamrarn; Guolin Zhang; Fei Wang
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.